keyword
MENU ▼
Read by QxMD icon Read
search

Agomelatin

keyword
https://www.readbyqxmd.com/read/28759866/oral-health-impacts-of-medications-used-to-treat-mental-illness
#1
N Cockburn, A Pradhan, M W Taing, S Kisely, P J Ford
BACKGROUND: Many psychotropic medications affect oral health. This review identified oral side effects for antidepressant, antipsychotic, anticonvulsant, antianxiety and sedative drugs that are recommended in Australia for the management of common mental illnesses and provides recommendations to manage these side-effects. METHODS: The Australian Therapeutic Guidelines and the Australian Medicines Handbook were searched for medications used to treat common mental health conditions...
July 23, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28745530/agomelatine-based-in-situ-gels-for-brain-targeting-via-the-nasal-route-statistical-optimization-in-vitro-and-in-vivo-evaluation
#2
Ahmed M Fatouh, Ahmed H Elshafeey, Ahmed Abdelbary
Agomelatine (AGM) is an antidepressant drug with a low absolute bioavailability due to the hepatic first pass metabolism. AGM-loaded solid lipid nanoparticles were formulated in the form of an in situ gel to prolong the intranasal retention time and subsequently to increase the absorbed amount of AGM. The optimized in situ gel formula had a sol-gel transition temperature of 31 °C ± 1.40, mucociliary transport time of 27 min ±1.41%, released after 1 and 8 h of 46.3% ± 0.85 and 70.90% ± 1...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28744157/the-abc7-regimen-a-new-approach-to-metastatic-breast-cancer-using-seven-common-drugs-to-inhibit-epithelial-to-mesenchymal-transition-and-augment-capecitabine-efficacy
#3
Richard E Kast, Nicolas Skuli, Samuel Cos, Georg Karpel-Massler, Yusuke Shiozawa, Ran Goshen, Marc-Eric Halatsch
Breast cancer metastatic to bone has a poor prognosis despite recent advances in our understanding of the biology of both bone and breast cancer. This article presents a new approach, the ABC7 regimen (Adjuvant for Breast Cancer treatment using seven repurposed drugs), to metastatic breast cancer. ABC7 aims to defeat aspects of epithelial-to-mesenchymal transition (EMT) that lead to dissemination of breast cancer to bone. As add-on to current standard treatment with capecitabine, ABC7 uses ancillary attributes of seven already-marketed noncancer treatment drugs to stop both the natural EMT process inherent to breast cancer and the added EMT occurring as a response to current treatment modalities...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28730851/agomelatine-for-the-treatment-of-generalized-anxiety-disorder
#4
Massimiliano Buoli, Silvia Grassi, Marta Serati, A Carlo Altamura
Agomelatine is a melatonergic antidepressant, approved for the treatment of Major Depressive Disorder (MDD) in Europe and Australia, but not in the United States. This compound seems to be promising in the short-term and maintenance treatment of Generalized Anxiety Disorder (GAD). Areas covered: This paper presents an evaluation of the available data about the clinical efficacy and tolerability of agomelatine in the treatment of GAD. Expert opinion: First-line GAD treatments are limited by high rates of lack of clinical response...
July 28, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28684900/intranasal-agomelatine-solid-lipid-nanoparticles-to-enhance-brain-delivery-formulation-optimization-and-in-vivo-pharmacokinetics
#5
Ahmed M Fatouh, Ahmed H Elshafeey, Ahmed Abdelbary
PURPOSE: Agomelatine is a novel antidepressant drug suffering from an extensive first-pass metabolism leading to a diminished absolute bioavailability. The aim of the study is: first to enhance its absolute bioavailability, and second to increase its brain delivery. METHODS: To achieve these aims, the nasal route was adopted to exploit first its avoidance of the hepatic first-pass metabolism to increase the absolute bioavailability, and second the direct nose-to-brain pathway to enhance the brain drug delivery...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28679194/acute-urinary-retention-after-venlafaxine-use
#6
Şaban Oğuz Demirdöğen, Esen Yıldırım Demirdöğen, Şenol Adanur
We describe a case of lower urinary system symptoms (LUSSs) and acute urinary retention that developed after treatment with a low dose of venlafaxine. A 48-year-old male patient was admitted to our clinic because of difficulty urinating, an intermittent stream, and trickling at the end of urination, together with urinary retention that had started about 45 days ago. The patient had been taking venlafaxine for the previous 6 months. The drug had been prescribed by the psychiatry department for a diagnosis of major depression, and the dose had been increased from 75 mg/day to 150 mg/day 1...
June 30, 2017: Archivio Italiano di Urologia, Andrologia
https://www.readbyqxmd.com/read/28663124/comparative-evaluation-of-vortioxetine-as-a-switch-therapy-in-patients-with-major-depressive-disorder
#7
Michael E Thase, Natalya Danchenko, Melanie Brignone, Ioana Florea, Francoise Diamand, Paula L Jacobsen, Eduard Vieta
Switching antidepressant therapy is a recommended strategy for depressed patients who neither respond to nor tolerate an initial pharmacotherapy course. This paper reviews the efficacy and tolerability of switching to vortioxetine. All three published studies of patients with major depressive disorder (MDD) switched from SSRI/SNRI therapy to vortioxetine due to lack of efficacy or tolerability were selected. Vortioxetine was evaluated versus agomelatine directly (REVIVE) and versus sertraline, venlafaxine, bupropion, and citalopram in an indirect treatment comparison (ITC) from switch studies retrieved in a literature review...
June 26, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28657181/effectiveness-of-agomelatine-on-anhedonia-in-depressed-patients-an-outpatient-open-label-real-world-study
#8
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28578215/effects-of-agomelatine-on-pentylenetetrazole-induced-kindling-kindling-associated-oxidative-stress-and-behavioral-despair-in-mice-and-modulation-of-its-actions-by-luzindole-and-1-m-chlorophenyl-piperazine
#9
M Suhaib Azim, Nidhi B Agarwal, Divya Vohora
In view of well-evidenced antiepileptic effects of melatonin and few reports of anticonvulsant action of agomelatine, the present study investigated whether agomelatine protects against pentylenetetrazole (PTZ)-induced kindling in mice and kindling-associated oxidative stress, depression, and impairment of spatial memory. In order to explore whether effects are mediated by melatonergic or serotonergic mechanisms, 1-(m-chlorophenyl) piperazine (mCPP), selective 5HT2c receptor agonist and luzindole, melatonergic receptor antagonist, were taken as pharmacological tools...
June 1, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28578027/agomelatine-a-mt1-mt2-melatonergic-receptor-agonist-with-serotonin-5-ht2c-receptor-antagonistic-properties-suppresses-prevotella-intermedia-lipopolysaccharide-induced-production-of-proinflammatory-mediators-in-murine-macrophages
#10
Jin-Yi Hyeon, Eun-Young Choi, So-Hui Choe, Hae Ryoun Park, Jeom-Il Choi, In Soon Choi, Sung-Jo Kim
OBJECTIVE: This study was performed in an attempt to examine the influence of agomelatine in mitigating the generation of proinflammatory mediators in RAW264.7 murine macrophages exposed to lipopolysaccharide (LPS) obtained from Prevotella intermedia, a gram-negative anaerobic bacterium that is related with various types of periodontal diseases, and the molecular mechanisms behind its effects. DESIGN: LPS from P. intermedia strain ATCC 25611 was prepared employing the conventional phenol-water procedure...
May 24, 2017: Archives of Oral Biology
https://www.readbyqxmd.com/read/28535406/anhedonia-predicts-poor-psychosocial-functioning-results-from-a-large-cohort-of-patients-treated-for-major-depressive-disorder-by-general-practitioners
#11
F Vinckier, D Gourion, S Mouchabac
BACKGROUND: Anhedonia is a core symptom of major depression and a key prognostic factor that is often poorly explored in clinical trials of major depressive disorder (MDD). Beyond symptomatic remission, psychosocial functioning also reveals difficulty in achieving remission in patients with MDD. The main objective of this study was to explore the interrelationships between social functioning and anhedonia on a longitudinal basis. METHODS: In total, 1570 outpatients treated for MDD with agomelatine were included...
July 2017: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/28500556/reversing-glioma-malignancy-a-new-look-at-the-role-of-antidepressant-drugs-as-adjuvant-therapy-for-glioblastoma-multiforme
#12
Anna M Bielecka-Wajdman, Marta Lesiak, Tomasz Ludyga, Aleksander Sieroń, Ewa Obuchowicz
PURPOSE: The role of glioma stem cells (GSCs) in cancer progression is currently debated; however, it is hypothesised that this subpopulation is partially responsible for therapeutic resistance observed in glioblastoma multiforme (GBM). Recent studies have shown that the current treatments not only fail to eliminate the GSC population but even promote GSCs through reprogramming of glioma non-stem cells to stem cells. Since the standard GBM treatment often requires supplementation with adjuvant drugs such as antidepressants, their role in the regulation of the heterogeneous nature of GSCs needs evaluation...
June 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28494335/ultrasound-assisted-low-density-solvent-dispersive-liquid-liquid-microextraction-for-the-simultaneous-determination-of-12-new-antidepressants-and-2-antipsychotics-in-whole-blood-by-gas-chromatography-mass-spectrometry
#13
Xiujuan Chen, Shuiqing Zheng, Jian Le, Zheyuan Qian, Runsheng Zhang, Zhanying Hong, Yifeng Chai
Antidepressant drugs are widely used in the treatment of different psychiatric disorders, as well as in conjunction with antipsychotics for the treatment of major depressive disorder. In this study, a simple and rapid ultrasound-assisted low-density solvent dispersive liquid-liquid microextraction (UA-LDS-DLLME) method was developed for the simultaneous determination of 12 new antidepressants (norfluoxetine, fluoxetine, fluvoxamine, agomelatine, mirtazapine, moclobemide, melitracen, N-desmethylmirtazapine, maprotiline, sertraline, citalopram, paroxetine) and 2 antipsychotics (clozapine and haloperidol) in human whole blood by gas chromatography-mass spectrometry (GC-MS)...
April 29, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28465217/antidepressants-induce-autophagy-dependent-nlrp3-inflammasome-inhibition-in-major-depressive-disorder
#14
Elísabet Alcocer-Gómez, Nieves Casas-Barquero, Matthew R Williams, Samuel L Romero-Guillena, Diego Cañadas-Lozano, Pedro Bullón, José Antonio Sánchez-Alcazar, José M Navarro-Pando, Mario D Cordero
Major Depressive Disorder (MDD, ICD-10: F-33) is a prevalent illness in which the pathogenic mechanism remains elusive. Recently an important role has been attributed to neuro-inflammation, and specifically the NLRP3-inflammasome complex, in the pathogenesis of MDD. This suggests a key role for immunomodulation as a key pathway in the treatment of this disorder. This study evaluates the involvement of nine common antidepressants in the NLRP3-inflammasome complex (fluoxetine, paroxetine, mianserin, mirtazapine, venlafaxine, desvenlafaxine, amitriptyline, imipramine and agomelatine), both in in vitro THP-1 cells stimulated by ATP, and in a stress-induced depressive animal or MDD patients...
May 2, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28461750/agomelatine-in-the-treatment-of-mild-to-moderate-depression-in-patients-with-cardiovascular-disease-results-of-the-national-multicenter-observational-study-pulse
#15
Vladimir E Medvedev
BACKGROUND: PULSE was a large, observational, multicenter study designed to evaluate the efficacy and safety of agomelatine in the treatment of major depression in patients with cardiovascular disease (CVD). METHODS: Patients with mild-to-moderate major depressive episodes, without psychotic symptoms, were treated as outpatients or in cardiac facilities in 46 regions of Russia. The patients received antidepressant monotherapy with agomelatine 25 or 50 mg, once daily, for 12 weeks...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28438504/agomelatine-protects-against-neuronal-damage-without-preventing-epileptogenesis-in-the-kainate-model-of-temporal-lobe-epilepsy
#16
Jana Tchekalarova, Dimitrinka Atanasova, Zlatina Nenchovska, Milena Atanasova, Lidia Kortenska, Rumyana Gesheva, Nikolai Lazarov
Recent studies about the novel antidepressant agomelatine, which is a mixed MT1 and MT2 melatonin receptor agonist and 5HT2C serotonin receptor antagonist possessing an anticonvulsant and neuroprotective action, suggest that it may have potential to contribute against epileptogenesis and epilepsy-induced memory impairment. In order to ascertain whether protection of some brain structures could suppress epileptogenesis, in the present study, we evaluated the effect of chronic post-status treatment with agomelatine on epileptogenesis, behavioral and neuronal damage induced by kainate acid (KA) status epilepticus (SE)...
April 21, 2017: Neurobiology of Disease
https://www.readbyqxmd.com/read/28399093/-the-differential-diagnosis-and-treatment-of-depressive-disorders-in-climacteric-transition
#17
N A Tyuvina, V V Balabanova, E O Voronina
AIM: To study clinical symptoms of menopause depression, develop differential diagnostic criteria and consider treatment aspects. MATERIAL AND METHODS: One hundred and fifty women, aged 41-65 years, with mental disorders developed in different periods of menopause (perimenopause, menopause and post menopause) were studied. RESULTS AND CONCLUSION: Four types of depression were diagnosed: climacteric (n=46), psychogenic (n=35), endogenic (n=42) and involutional (n=27)...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28392509/bioequivalence-and-pharmacokinetic-profiles-of-agomelatine-25-mg-tablets-in-healthy-chinese-subjects-a-four-way-replicate-crossover-study-demonstrating-high-intra-and-inter-individual-variations
#18
Cuiyun Li, Jing Xu, Yan Zheng, Guiling Chen, Jianmeng Wang, Liying Ma, Yan Qiao, Junqi Niu, Min Wu, Hong Zhang, Xiaojiiao Li, Hong Chen, Xiaoxue Zhu, Chengjiao Liu, Yanhua Ding
The present study was designed to assess the bioequivalence of two agomelatine formulations (25-mg tablets) in healthy Chinese male subjects. This single-dose, open-label, randomized, four-way replicate study with a 1-week washout period was conducted in 60 healthy Chinese male volunteers under fasting conditions. Blood samples were collected over a 12-h period after a single dose of the 25-mg agomelatine test (T) formulation or a reference (R) formulation, and the drug concentrations were assayed by liquid chromatography tandem mass spectrometry (LC-MS/MS)...
June 1, 2017: Chemical & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28383308/antidepressant-effect-in-older-depressed-patients-the-lessons-of-two-agomelatine-trials
#19
Guy M Goodwin, Pierre Thomas, Reinhard Heun, Patrice Boyer, Françoise Picarel-Blanchot, Christian de Bodinat
The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28374847/effect-of-agomelatine-on-memory-deficits-and-hippocampal-gene-expression-induced-by-chronic-social-defeat-stress-in-mice
#20
Vincent Martin, Najib Allaïli, Marine Euvrard, Tevrasamy Marday, Armance Riffaud, Bernard Franc, Elisabeth Mocaër, Cecilia Gabriel, Philippe Fossati, Stéphane Lehericy, Laurence Lanfumey
Chronic stress is known to induce not only anxiety and depressive-like phenotypes in mice but also cognitive impairments, for which the action of classical antidepressant compounds remains unsatisfactory. In this context, we investigated the effects of chronic social defeat stress (CSDS) on anxiety-, social- and cognitive-related behaviors, as well as hippocampal Bdnf, synaptic plasticity markers (PSD-95, Synaptophysin, Spinophilin, Synapsin I and MAP-2), and epigenetic modifying enzymes (MYST2, HDAC2, HDAC6, MLL3, KDM5B, DNMT3B, GADD45B) gene expression in C57BL/6J mice...
April 4, 2017: Scientific Reports
keyword
keyword
118315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"